SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

American Renal Associates Holdings, Inc. – ‘10-Q’ for 3/31/17 – ‘R24’

On:  Tuesday, 5/9/17, at 4:50pm ET   ·   For:  3/31/17   ·   Accession #:  1498068-17-35   ·   File #:  1-37751

Previous ‘10-Q’:  ‘10-Q’ on 11/10/16 for 9/30/16   ·   Next:  ‘10-Q’ on 8/8/17 for 6/30/17   ·   Latest:  ‘10-Q’ on 11/6/20 for 9/30/20

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 5/09/17  American Renal Assocs Holdin… Inc 10-Q        3/31/17   73:5M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    520K 
 2: EX-10.1     Material Contract                                   HTML     43K 
 3: EX-10.2     Material Contract                                   HTML     40K 
 4: EX-10.3     Material Contract                                   HTML     39K 
 5: EX-10.4     Material Contract                                   HTML     41K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     22K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     22K 
16: R1          Document and Entity Information                     HTML     41K 
17: R2          Consolidated Balance Sheets                         HTML    115K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     44K 
19: R4          Consolidated Statements of Operations               HTML     81K 
20: R5          Consolidated Statements of Comprehensive (Loss)     HTML     35K 
                Income                                                           
21: R6          Consolidated Statement of Changes in Equity         HTML     78K 
22: R7          Consolidated Statements of Cash Flows               HTML    114K 
23: R8          Basis of Presentation and Organization              HTML     38K 
24: R9          Initial Public Offering                             HTML     41K 
25: R10         Cash                                                HTML     29K 
26: R11         Accounts Receivable                                 HTML     28K 
27: R12         Fair Value Measurements                             HTML     91K 
28: R13         Accrued Expenses and Other Current Liabilities      HTML     37K 
29: R14         Variable Interest Entities                          HTML     29K 
30: R15         Noncontrolling Interests Subject to Put Provisions  HTML     38K 
31: R16         Debt                                                HTML     52K 
32: R17         Income Taxes                                        HTML     27K 
33: R18         Stock-Based Compensation                            HTML     64K 
34: R19         (Loss) Earnings Per Share                           HTML     55K 
35: R20         Related Party Transactions                          HTML     35K 
36: R21         Commitments and Contingencies                       HTML     27K 
37: R22         Certain Legal Matters                               HTML     34K 
38: R23         Changes in Ownership Interest in Consolidated       HTML     38K 
                Subsidiaries                                                     
39: R24         Basis of Presentation and Organization (Policies)   HTML     40K 
40: R25         Cash (Tables)                                       HTML     34K 
41: R26         Fair Value Measurements (Tables)                    HTML     84K 
42: R27         Accrued Expenses and Other Current Liabilities      HTML     38K 
                (Tables)                                                         
43: R28         Debt (Tables)                                       HTML     47K 
44: R29         Stock-Based Compensation (Tables)                   HTML     64K 
45: R30         (Loss) Earnings Per Share (Tables)                  HTML     52K 
46: R31         Changes in Ownership Interest in Consolidated       HTML     35K 
                Subsidiaries (Tables)                                            
47: R32         Basis of Presentation and Organization (Details)    HTML     51K 
48: R33         Initial Public Offering (Details)                   HTML    107K 
49: R34         Cash (Details)                                      HTML     29K 
50: R35         Accounts Receivable (Details)                       HTML     30K 
51: R36         Fair Value Measurements (Details)                   HTML     30K 
52: R37         Fair Value Measurements - Schedule of fair values   HTML     58K 
                (Details)                                                        
53: R38         FAIR VALUE MEASUREMENTS - Fair value rollforward    HTML     30K 
                for tax receivable agreement liability (Details)                 
54: R39         Accrued Expenses and Other Current Liabilities      HTML     41K 
                (Details)                                                        
55: R40         Variable Interest Entities (Details)                HTML     24K 
56: R41         Noncontrolling Interests Subject to Put Provisions  HTML     25K 
                (Details)                                                        
57: R42         DEBT - Schedule of long-term debt (Details)         HTML     41K 
58: R43         DEBT - Scheduled maturities of long-term debt       HTML     40K 
                (Details)                                                        
59: R44         DEBT - Narrative (Details)                          HTML     51K 
60: R45         Income Taxes (Details)                              HTML     28K 
61: R46         STOCK-BASED COMPENSATION - Schedule of Expense      HTML     30K 
                (Details)                                                        
62: R47         STOCK-BASED COMPENSATION - Narrative (Details)      HTML     48K 
63: R48         STOCK-BASED COMPENSATION - Assumptions used for     HTML     33K 
                options granted (Details)                                        
64: R49         STOCK-BASED COMPENSATION - Option activity          HTML     54K 
                (Details)                                                        
65: R50         STOCK-BASED COMPENSATION - Restricted stock awards  HTML     40K 
                (Details)                                                        
66: R51         (Loss) Earnings Per Share (Details)                 HTML     56K 
67: R52         Related Party Transactions (Details)                HTML     58K 
68: R53         Commitments and Contingencies (Details)             HTML     22K 
69: R54         Certain Legal Matters (Details)                     HTML     28K 
70: R55         Changes in Ownership Interest in Consolidated       HTML     34K 
                Subsidiaries (Details)                                           
72: XML         IDEA XML File -- Filing Summary                      XML    121K 
71: EXCEL       IDEA Workbook of Financial Reports                  XLSX     67K 
10: EX-101.INS  XBRL Instance -- ara-20170331                        XML   1.02M 
12: EX-101.CAL  XBRL Calculations -- ara-20170331_cal                XML    194K 
13: EX-101.DEF  XBRL Definitions -- ara-20170331_def                 XML    428K 
14: EX-101.LAB  XBRL Labels -- ara-20170331_lab                      XML   1.34M 
15: EX-101.PRE  XBRL Presentations -- ara-20170331_pre               XML    757K 
11: EX-101.SCH  XBRL Schema -- ara-20170331                          XSD    126K 
73: ZIP         XBRL Zipped Folder -- 0001498068-17-000035-xbrl      Zip    165K 


‘R24’   —   Basis of Presentation and Organization (Policies)


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.7.0.1
BASIS OF PRESENTATION AND ORGANIZATION (Policies)
3 Months Ended
Accounting Policies [Abstract]  
Basis of Presentation and Consolidation
Basis of Presentation and Consolidation
 
The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“U.S.”) for complete financial statements. Our consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and variable interest entities that operate its clinics (“joint ventures”). All significant intercompany balances and transactions of our wholly owned subsidiaries and joint ventures, including management fees from subsidiaries, are eliminated in consolidation. Refer to Note 6 – Variable Interest Entities.
 
In the opinion of management, the Company has prepared the accompanying unaudited consolidated financial statements on the same basis as its audited financial statements, and these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results of the interim periods presented.  These unaudited consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016.  Prior year balances and amounts have been reclassified to conform to the current year presentation. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year.
Segment Information
Segment Information
 
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker as of March 31, 2017, or decision-making group, in making decisions how to allocate resources and assess performance. The Company’s chief decision-maker is a combination of the Chief Executive Officer and the President. The Company views its operations and manages its business as one reportable business segment, the ownership and operation of dialysis clinics, all of which are located in the United States.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
 
In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-18, Statement of Cash Flows (Topic 230). The objective of this update is to provide additional guidance and reduce diversity in practice when classifying certain transactions within the statement of cash flows. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new standard requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. These standards are effective for financial statements issued for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted for all organizations. The Company adopted the provisions of ASU 2016-18 as of January 1, 2017 and applied it retrospectively for all periods presented, which did not have a material impact on the Company's financial statements.

In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718) – Improvements to Employee Share-Based Payment Accounting. The ASU identifies areas for simplification involving several aspects of share-based payment transactions, including the income tax consequences, classification of awards as equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early application is permitted for all organizations, and the Company adopted the provisions of ASU 2016-09 as of July 1, 2016.   Upon early adoption, the Company elected to change its accounting policy to account for forfeitures as they occur.  The change was applied on a modified retrospective basis resulting in an increase to stock compensation expense for the six months ended June 30, 2016 of $354.  Amendments related to accounting for excess tax benefits have been adopted prospectively, resulting in recognition of excess tax benefits against income tax expenses rather than additional paid-in capital of $225 for the six months ended June 30, 2016.  Excess tax benefits for share-based payments are included in net operating cash rather than net financing cash, which is consistent with the Company’s current policy.
 
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) – Leases: Amendments to the FASB Accounting Standards Codification. The amendments are expected to increase transparency and comparability by recognizing lease assets and liabilities from lessees on the balance sheet and disclosing key information about leasing arrangements in the financial statements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all organizations. The Company expects a balance sheet extension due to the “on balance sheet” recognition of right of use assets and liabilities for agreed lease payment obligations related to certain leased clinics and buildings which are currently classified as operating leases. The impact on the Company will depend on the contract portfolio at the effective date, as well as the transition method. The Company expects to apply the modified retrospective method after review of the analysis is performed. We are currently assessing the impact the adoption of ASU 2016-02 will have on our consolidated financial statements.
 
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. The new standard also requires entities to enhance disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The new standard allows for either a full retrospective or a modified retrospective transition method and is effective for fiscal years beginning after December 15, 2016. In July 2015 the FASB issued ASU 2015-14, which defers the effective date of ASU 2014-09 for one year, making ASU 2014-09 effective for annual reporting periods beginning on or after December 15, 2017 while also providing for early adoption but not before the original effective date. The FASB has issued additional updates to serve as clarification to the original standard update. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on our consolidated financial statements.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
12/15/18
12/15/174,  8-K
Filed on:5/9/178-K
For Period end:3/31/17
1/1/17
12/31/1610-K
12/15/16
7/1/168-K
6/30/1610-Q
 List all Filings 
Top
Filing Submission 0001498068-17-000035   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 1, 12:35:19.0pm ET